1-3 of 3
Sybil H Zildjian, MPH
Close
Sort by
Journal Articles

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anastasios Stathis, MD, Arnold S. Freedman, MD, Ian W. Flinn, MD, Kami J. Maddocks, MD, Steven Weitman, MDPhD, Jesus G. Berdeja, MD, Alex V. Mejia, MD, Emanuele Zucca, MD, Rebecca Green, Angela Romanelli, PhD, Sybil H Zildjian, MPH, Rodrigo Ruiz-Soto, MD MSc, Lia Palomba, MD
Journal: Blood
Blood (2014) 124 (21): 1760.
https://doi.org/10.1182/blood.V124.21.1760.1760
Published: 2014
Journal Articles

Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis

Asher Chanan-Khan, MD, Jeffrey L Wolf, MD, Juan Garcia, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Debbie Manfredi, Taimur Sher, MD, Cindi Martin, Sybil H Zildjian, MPH, James O'Leary, MD, Robert Vescio, MD
Journal: Blood
Blood (2010) 116 (21): 1962.
https://doi.org/10.1182/blood.V116.21.1962.1962
Published: 2010
Journal Articles

Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination

Jesus G Berdeja, MD, Sikander Ailawadhi, MD, Ruben Niesvizky, MD, Jeffrey L Wolf, MD, Sybil H Zildjian, MPH, James O'Leary, MD, Asher Chanan-Khan, MD
Journal: Blood
Blood (2010) 116 (21): 1934.
https://doi.org/10.1182/blood.V116.21.1934.1934
Published: 2010